6:25 PM
Nov 15, 2013
 |  BC Extra  |  Clinical News

Zafgen's beloranib leads to significant weight loss

Zafgen Inc. (Cambridge, Mass.) presented final 12-week data on Friday from 122 evaluable patients in a Phase IIa trial evaluating subcutaneous beloranib ( ZGN-440) to treat obesity. Twice-weekly 0.6, 1.2 and 2.4 mg subcutaneous beloranib each met the co-primary endpoint of greater mean weight loss from baseline...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >